CNB-001 is a research compound that potently inhibits 5-lipoxygenase (5-LOX), reducing its expression and enhancing proteasome activity. In Alzheimer's disease models, it modulates eIF2α phosphorylation, HSP90, and ATF4 to limit Aβ and aggregated proteins, while preserving synaptic markers and improving memory, making it valuable for neurodegenerative disease research.